Adherence to treatment in Swedish HIV-infected patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 6, 2006, Pages 605-616

  Sodergard B ^a,b   Halvarsson, M ^b   Tully, M P ^a,c   Mindouri, S ^a   Nordstrom M L ^a   Lindback S ^b   Sonnerborg A ^b   Lindblad, A K ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acquired immunodeficiency syndrome; Highly active antiretroviral therapy; Human immunodeficiency virus; Patient compliance; Sweden

Indexed keywords

ALCOHOL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ALCOHOL ABUSE; ARTICLE; CLINICAL ARTICLE; DOCTOR PATIENT RELATION; DRUG ABUSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM EXPOSURE; MALE; PATIENT COMPLIANCE; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SCORING SYSTEM; SWEDEN;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; SOCIAL SUPPORT; SWEDEN;

EID: 33751366819     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00782.x     Document Type: Article

References (61)

1. Smittskyddsinstitutet (2003) Surveillance statistics 2003: HIV infection/AIDS. [cited 2004, 2004-09-04]; Available from: http://www. smittskyddsinstitutet.se/SMItemplates/Article.aspx?id=2834.
2. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT et al. (1998) Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA, 279, 450-454.
3. Murphy EL, Collier AC, Kalish LA et al. (2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of Internal Medicine, 135, 17-26.
4. Palella FJ Jr, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853-860.
5. Powderly WG, Landay A, Lederman MM (1998) Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA, 280, 72-77.
6. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP (1999) Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. Journal of Infectious Diseases, 179, 717-720.
7. Paterson DL, Swindells S, Mohr J et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
8. Liu H, Golin CE, Miller LG et al. (2001) A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134, 968-977.
9. Arnsten JH, Demas PA, Farzadegan H et al. (2001) Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33, 1417-1423.
10. Wagner GJ, Rabkin JG (2000) Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care, 12, 405-408.
11. Bangsberg DR, Hecht FM, Charlebois ED et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14, 357-366.
12. Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A (2001) Comparing objective measures of adherence to HIVantiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS and Behavior, 5, 275-281.
13. Ostrop NJ, Hallett KA, Gill MJ (2000) Long-term patient adherence to antiretroviral therapy. Annals of Pharmacotherapy, 34, 703-709.
14. Roberts KJ (2000) Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care STDS, 14, 155-168.
15. Ammassari A, Trotta MP, Murri R et al. (2002) Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl.3), S123-S127.
16. Ammassari A, Murri R, Pezzotti P et al. (2001) Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28, 445-449.
17. Muma RD, Ross MW, Parcel GS, Pollard RB (1995) Zidovudine adherence among individuals with HIV infection. AIDS Care, 7, 439-447.
18. Murri R, Ammassari A, De Luca A et al. (2001) Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clinical Trials, 2, 323-329.
19. Nieuwkerk P, Gisolf E, Sprangers M, Danner S (2001) Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. Antiviral Therapy, 6, 97-103.
20. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP (2002) Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Social Science and Medicine, 54, 1481-1496.
21. van Servellen G, Chang B, Garcia L, Lombardi E (2002) Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS, 16, 269-281.
22. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB (2004) Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. Journal of General Internal Medicine, 19, 96-103.
23. Roberts KJ (2002) Physician-patient relationships, patient satisfaction, and antiretroviral medication. Adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDS, 16, 43-50.
24. Stone VE, Clarke J, Lovell J et al. (1998) HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. Journal of General Internal Medicine, 13, 586-593.
25. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J (1999) Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1763-1769.
26. Kemppainen JK, Levine RE, Mistal M, Schmidgall D (2001) HAART adherence in culturally diverse patients with HIV/AIDS: a study of male patients from a Veteran's Administration Hospital in northern California. AIDS Patient Care STDS, 15, 117-127.
27. Ammassari AA, Starace F, Aloisi MS et al. (2003) Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology, 61, 723-724; author reply 4.
28. Kalichman SC, Ramachandran B, Catz S (1999) Adherence to combination antiretroviral therapies in HIV patients of low health literacy. Journal of General Internal Medicine, 14, 267-273.
29. Carrieri P, Cailleton V, Le Moing V et al. (2001) The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndrome, 28, 232-239.
30. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M (2001) Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care, 13, 27-40.
31. Golin CE, Liu H, Hays RD et al. (2002) A prospective study of predictors of adherence to combination antiretroviral medication. Journal of General Internal Medicine, 17, 756-765.
32. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C (2000) The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care, 12, 387-398.
33. Cederfjall C, Langius-Eklof A, Lidman K, Wredling R (2002) Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients. Aids Patient Care and STDS, 16, 609-616.
34. Schonnesson LN, Ross MW, Williams M (2004) The HIV Medication Self-Reported Nonadherence Reasons (SNAR) Index and Its Underlying Psychological Dimensions. AIDS Behaviour, 8, 293-301.
35. Sodergard B, Halvarsson M, Lindback S, Sonnerborg A, Tully M, Kettis Lindblad A (2006) Differences in adherence and motivation to HIV therapy - two independent assessments in 1998 and 2002. Pharmacy World & Science, in press.
36. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24, 67-74.
37. Morisky DE, Ward HJ, Liu K-Y (2001) Self-reported medication taking behaviour: a valid Indicator for assessing compliance. Presentation at the 129th American Public Health Association Meeting, Atlanta.
38. Viswanathan H, Anderson R, Thomas J 3rd (2005) Nature and correlates of SF-12 physical and mental quality of life components among low-income HIV adults using an HIV service center. Quality of Life Research, 14, 935-944.
39. Viswanathan H, Anderson R, Thomas J 3rd (2005) Evaluation of an antiretroviral medication attitude scale and relationships between medication attitudes and medication nonadherence. AIDS Patient Care STDS, 19, 306-316.
40. Chesney MA, Ickovics JR, Chambers DB et al. (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12, 255-266.
41. Petrie A, Sabin C (2000) Medical statistics at a glance. Malden: Blackwell Science Ltd.
42. Haubrich RH, Little SJ, Currier JS et al. (1999) The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS, 13, 1099-1107.
43. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. (1996) Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care, 8, 261-269.
44. Levine AJ, Hinkin CH, Castellon SA et al. (2005) Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behaviour, 9, 1-8.
45. Kleeberger CA, Buechner J, Palella F et al. (2004) Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. Aids, 18, 683-688.
46. Murphy DA, Marelich WD, Hoffman D, Steers WN (2004) Predictors of antiretroviral adherence. AIDS Care, 16, 471-484.
47. Hinkin CH, Hardy DJ, Mason KI et al. (2004) Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS, 18(Suppl.1), S19-S25.
48. Nordqvist O, Sodergard B, Tully MP, Sonnerborg A, Lindblad AK (2006) Assessing and achieving readiness to initiate HIV medication. Patient Education and Counseling, 62, 21-30.
49. Enriquez M, Lackey NR, O'Connor MC, McKinsey DS (2004) Successful adherence after multiple HIV treatment failures. Journal of Advanced Nursing, 45, 438-446.
50. Nichols SE (1985) Psychosocial reactions of persons with the acquired immunodeficiency syndrome. Annals of Internal Medicine, 103, 765-767.
51. Bakken S, Holzemer WL, Brown MA et al. (2000) Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS, 14, 189-197.
52. Wagner GJ (2002) Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS, 16, 599-608.
53. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S et al. (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17, 1925-1932.
54. Stockwell Morris L, Schultz RM (1992) Patient compliance - an overview. Journal of Clinical Pharmacy and Therapeutics, 17, 283-295.
55. Pehrson P, Halvarsson M (2002) Can it be better - 85% with VL < 50 after medium treatment for 55 months? Glasgow, UK: Sixth International Congress on Drug therapy in HIV infection.
56. Darlington P, Ahlqvist M, Halvarsson M, Pehrson P (2003) To be challenged - 86% with VL < 50 after medium treatment for 69 months? Warsaw, Poland: 9th European AIDS Conference (EACS).
57. Lucas GM, Chaisson RE, Moore RD (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81-87.
58. Kaufmann GR, Perrin L, Pantaleo G et al. (2003) CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Archives of Internal Medicine, 163, 2187-2195.
59. Sodergard BM, Baretta K, Tully MP, Kettis Lindblad AM (2005) A qualitative study of health-care personnel's experience of a satellite pharmacy at a HIV clinic. Pharmacy World & Science, 27, 108-115.
60. Jallow A, Kälvemark S, Persson PM, Hellgren U, Ericsson Ö (2003) Identification and comparison of problems in HIV infected homo- or bisexuals, former injecting drug users and Africans receiving antiretroviral therapy in Sweden, Research report. Stockholm: Apoteket AB.
61. DiMatteo MR (2004) Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Medical Care, 42, 200-209.